摘要
目的 分析和评价肾移植后肝功能不良患者使用霉酚酸酯（ＭＭＦ） 的有效性和安全性。方法 １２ 例患者术后免疫抑制方案为：９ 例采用环孢素Ａ（ＣｓＡ） 、硫唑嘌呤（Ａｚａ）、泼尼松（Ｐｒｅｄ） ；３例采用ＣｓＡ、Ｐｒｅｄ。发生肝功能不良后， 停用Ａｚａ；９ 例采用三联治疗的患者，６ 例减少ＣｓＡ 用量１／４～１／３ ，３ 例改用ＣｓＡ、Ｐｒｅｄ；３ 例采用二联治疗者，１ 例减少ＣｓＡ 用量，２ 例停用ＣｓＡ；１２ 例均加用ＭＭＦ１ ．５ ～２．０ ｇ／ｄ。结果 １１ 例肝功能恢复正常， 无新的排斥发生。结论 ＭＭＦ是一种强有力的免疫抑制剂， 无肝、肾毒性， 移植后肝功能不良患者使用ＭＭＦ， 可停用Ａｚａ， 减少ＣｓＡ 用量， 不增加排斥的发生。
Objectives To analyze and evaluate the efficacy and safety of MMF in kidney transplant recipients with hepatic dysfunction. Methods Twelve liver dysfunction renal transplant recipients were treated with MMF ( 1.5 to 2.0 ?g/d). All patients discontinued Aza. Nine patients reduced cyclosporine A dose by 1/4 to 1/3.Liver function,rejection episodes and MMF adverse events were followed up for 6 months. Results By 6 months after using MMF, 11 of those patients got a normal liver function. No denova rejection episodes were observed during the six month. Conclusions MMF is a new potent immunosuppressive agent without hepatic or nephrotoxicity.In those liver dysfunction transplant recipients, the use of MMF can lead to Aza cessation and cyclosporine A reduction without increased rejection episode.
出处
《中华器官移植杂志》
CAS
CSCD
2000年第1期17-18,共2页
Chinese Journal of Organ Transplantation
